Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation

Pediatr Cardiol. 2009 Nov;30(8):1176-9. doi: 10.1007/s00246-009-9521-3.

Abstract

Hypertrophic cardiomyopathy (HCM) is a heterogeneous disorder characterized by thickening of the heart and an increased incidence of sudden death. This study is aimed to determine the genetic cause of severe cardiac hypertrophy in an infant. An infant was assigned a diagnosis of ventricular preexcitation and severe biventricular HCM requiring septal myectomy. Genetic testing showed a novel heterozygous E506Q mutation of the adenosine monophosphate (AMP)-activated protein kinase (PRKAG2) gene. Endomyocardial biopsy samples did not demonstrate significant glycogen accumulation. Hypertrophic cardiomyopathy due to PRKAG2 mutations may have a degree of cardiac hypertrophy exceeding that expected from observed amounts of glycogen deposition.

Publication types

  • Case Reports

MeSH terms

  • AMP-Activated Protein Kinases / genetics*
  • Cardiomyopathy, Hypertrophic / diagnosis
  • Cardiomyopathy, Hypertrophic / genetics*
  • Cardiomyopathy, Hypertrophic / surgery
  • Electrocardiography
  • Glycogen / analysis
  • Humans
  • Infant
  • Male
  • Myocardium / chemistry
  • Myocardium / ultrastructure
  • Risk Factors

Substances

  • Glycogen
  • PRKAG2 protein, human
  • AMP-Activated Protein Kinases